Neumora Therapeutics Files 8-K
Ticker: NMRA · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-statements
TL;DR
Neumora filed an 8-K on Jan 2, 2025. Standard reporting.
AI Summary
Neumora Therapeutics, Inc. filed an 8-K on January 2, 2025, reporting other events and financial statements. The company, formerly known as RBNC Therapeutics, Inc. until September 29, 2021, is incorporated in Delaware and headquartered in Watertown, Massachusetts.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This filing appears to be a routine corporate disclosure and does not contain information suggesting immediate or significant risk.
Key Numbers
- 001-41802 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-4367680 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Registrant
- RBNC Therapeutics, Inc. (company) — Former company name
- January 2, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Watertown, Massachusetts (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond listing it as an item information category.
What is the significance of the 'Financial Statements and Exhibits' being filed?
This indicates that the company is providing updated financial information and supporting documents as required by the SEC.
When did Neumora Therapeutics, Inc. change its name from RBNC Therapeutics, Inc.?
The date of the name change was September 29, 2021.
Where are Neumora Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472.
What is the Standard Industrial Classification (SIC) code for Neumora Therapeutics, Inc.?
The SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-01-02 07:10:30
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share NMRA The Nasdaq
Filing Documents
- d859264d8k.htm (8-K) — 24KB
- d859264dex991.htm (EX-99.1) — 27KB
- g859264g0102104044225.jpg (GRAPHIC) — 3KB
- 0001193125-25-000084.txt ( ) — 181KB
- nmra-20250102.xsd (EX-101.SCH) — 3KB
- nmra-20250102_lab.xml (EX-101.LAB) — 18KB
- nmra-20250102_pre.xml (EX-101.PRE) — 11KB
- d859264d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUMORA THERAPEUTICS, INC. Date: January 2, 2025 By: /s/ Joshua Pinto, Ph.D. Joshua Pinto, Ph.D. Chief Financial Officer